Clinical Trial Update: A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers [Phase 2]

View source ↗

Summary

This Phase 2 trial aims to evaluate whether reducing the dosing frequency of immune checkpoint inhibitors is feasible across advanced cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Cancer
• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Carcinoma, Hepatocellular, Gastric Adenocarcinoma | Phase 2 | Status: RECRUITING